Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2024 | 2914 | 2.850 |
Why?
|
| Cerebellar Neoplasms | 8 | 2024 | 478 | 2.730 |
Why?
|
| Medulloblastoma | 7 | 2024 | 572 | 2.500 |
Why?
|
| Methotrexate | 6 | 2024 | 1025 | 1.880 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 551 | 1.840 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 132 | 1.640 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2024 | 125 | 1.600 |
Why?
|
| Firefighters | 4 | 2016 | 32 | 1.540 |
Why?
|
| Overweight | 5 | 2022 | 484 | 1.540 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2024 | 1348 | 1.510 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 98 | 0.970 |
Why?
|
| Cancer Survivors | 7 | 2022 | 744 | 0.940 |
Why?
|
| Child | 36 | 2024 | 30496 | 0.930 |
Why?
|
| Obesity | 6 | 2020 | 2911 | 0.900 |
Why?
|
| Metabolomics | 3 | 2021 | 505 | 0.860 |
Why?
|
| DNA Methylation | 6 | 2020 | 2764 | 0.850 |
Why?
|
| Weight Loss | 3 | 2016 | 632 | 0.790 |
Why?
|
| Metabolome | 2 | 2021 | 355 | 0.770 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 47 | 0.750 |
Why?
|
| Down Syndrome | 2 | 2022 | 227 | 0.720 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 2348 | 0.720 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 22 | 0.700 |
Why?
|
| Child, Preschool | 20 | 2024 | 16999 | 0.690 |
Why?
|
| Hypothyroidism | 1 | 2021 | 208 | 0.670 |
Why?
|
| Cisplatin | 4 | 2024 | 2497 | 0.670 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 517 | 0.670 |
Why?
|
| Survivors | 4 | 2022 | 1022 | 0.650 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 327 | 0.640 |
Why?
|
| Neonatal Screening | 1 | 2020 | 188 | 0.610 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 373 | 0.600 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 387 | 0.590 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 131 | 0.570 |
Why?
|
| Weight Gain | 2 | 2019 | 470 | 0.550 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 552 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2020 | 4648 | 0.520 |
Why?
|
| Ear Diseases | 1 | 2015 | 23 | 0.510 |
Why?
|
| Male | 35 | 2024 | 128105 | 0.490 |
Why?
|
| Proton Therapy | 2 | 2024 | 1635 | 0.490 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 863 | 0.470 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 269 | 0.470 |
Why?
|
| Bone Marrow | 1 | 2021 | 2439 | 0.450 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 4955 | 0.430 |
Why?
|
| Humans | 48 | 2024 | 270457 | 0.430 |
Why?
|
| Biomarkers | 2 | 2021 | 5054 | 0.420 |
Why?
|
| Mucositis | 2 | 2024 | 148 | 0.420 |
Why?
|
| Adolescent | 17 | 2024 | 32671 | 0.410 |
Why?
|
| Neoplasms | 4 | 2022 | 15905 | 0.390 |
Why?
|
| Genome, Human | 1 | 2020 | 1885 | 0.380 |
Why?
|
| DNA | 1 | 2020 | 3049 | 0.380 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 745 | 0.380 |
Why?
|
| Female | 30 | 2024 | 148644 | 0.380 |
Why?
|
| Leukemia | 1 | 2020 | 1720 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1387 | 0.370 |
Why?
|
| Health Status | 1 | 2014 | 630 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 5774 | 0.360 |
Why?
|
| Prognosis | 9 | 2024 | 22475 | 0.350 |
Why?
|
| Hearing Loss | 2 | 2024 | 173 | 0.340 |
Why?
|
| Genetic Variation | 3 | 2019 | 2165 | 0.330 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 1145 | 0.320 |
Why?
|
| Hypospadias | 2 | 2020 | 82 | 0.310 |
Why?
|
| Body Mass Index | 5 | 2020 | 2239 | 0.310 |
Why?
|
| Infant | 9 | 2024 | 13939 | 0.310 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 322 | 0.270 |
Why?
|
| Fatigue | 3 | 2022 | 1278 | 0.270 |
Why?
|
| Laxatives | 1 | 2024 | 17 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 15191 | 0.240 |
Why?
|
| Retrospective Studies | 8 | 2024 | 39751 | 0.230 |
Why?
|
| Incidence | 4 | 2022 | 5812 | 0.230 |
Why?
|
| Cochlea | 1 | 2024 | 118 | 0.230 |
Why?
|
| Creatinine | 2 | 2023 | 528 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 1066 | 0.220 |
Why?
|
| Constipation | 1 | 2024 | 189 | 0.220 |
Why?
|
| Counselors | 1 | 2023 | 27 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 64 | 0.210 |
Why?
|
| Intelligence | 1 | 2023 | 134 | 0.210 |
Why?
|
| Censuses | 1 | 2022 | 15 | 0.210 |
Why?
|
| Cultural Competency | 1 | 2023 | 70 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 5104 | 0.210 |
Why?
|
| Asparaginase | 1 | 2022 | 198 | 0.190 |
Why?
|
| Genotype | 3 | 2020 | 4251 | 0.190 |
Why?
|
| Growth Hormone | 1 | 2021 | 222 | 0.190 |
Why?
|
| Risk Factors | 9 | 2022 | 17849 | 0.190 |
Why?
|
| Genetic Counseling | 1 | 2023 | 417 | 0.180 |
Why?
|
| Executive Function | 1 | 2021 | 145 | 0.180 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 20 | 0.180 |
Why?
|
| Biliary Atresia | 1 | 2023 | 201 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2022 | 221 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 340 | 0.170 |
Why?
|
| Neutropenia | 1 | 2024 | 1007 | 0.170 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 210 | 0.170 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 1485 | 0.170 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 53 | 0.170 |
Why?
|
| Pancreatitis | 1 | 2022 | 295 | 0.170 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 23 | 0.170 |
Why?
|
| Forecasting | 1 | 2022 | 704 | 0.170 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 76 | 0.160 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 144 | 0.160 |
Why?
|
| Protons | 1 | 2021 | 482 | 0.160 |
Why?
|
| Sleep | 1 | 2021 | 443 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2023 | 6204 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2020 | 357 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 154 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2020 | 302 | 0.150 |
Why?
|
| Young Adult | 7 | 2024 | 22152 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 342 | 0.150 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 1443 | 0.150 |
Why?
|
| Adult | 13 | 2024 | 81754 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2020 | 9466 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 322 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2019 | 726 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 376 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 506 | 0.140 |
Why?
|
| Adiposity | 2 | 2020 | 238 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 74 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2019 | 1247 | 0.140 |
Why?
|
| Age Factors | 4 | 2024 | 5462 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 681 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2022 | 2854 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2221 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 318 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2015 | 41 | 0.130 |
Why?
|
| Computational Biology | 1 | 2021 | 1292 | 0.120 |
Why?
|
| SEER Program | 1 | 2019 | 1049 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 787 | 0.120 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 14623 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 347 | 0.120 |
Why?
|
| Neutrophils | 1 | 2019 | 867 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2014 | 100 | 0.120 |
Why?
|
| Registries | 1 | 2022 | 2204 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 517 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1046 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2019 | 1272 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 3999 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1743 | 0.110 |
Why?
|
| Prevalence | 2 | 2022 | 3357 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 797 | 0.100 |
Why?
|
| Recurrence | 1 | 2020 | 4877 | 0.100 |
Why?
|
| Counseling | 1 | 2014 | 382 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1099 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1957 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 656 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 2634 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 4480 | 0.090 |
Why?
|
| Pediatrics | 1 | 2019 | 1187 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8626 | 0.080 |
Why?
|
| Middle Aged | 4 | 2019 | 90100 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 2591 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 740 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2020 | 13383 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 5142 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 10262 | 0.070 |
Why?
|
| United States | 4 | 2018 | 15856 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 5001 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 671 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2019 | 5438 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2020 | 5672 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 7014 | 0.060 |
Why?
|
| Mediator Complex | 1 | 2023 | 67 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 79 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 330 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10697 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 432 | 0.050 |
Why?
|
| Homozygote | 1 | 2023 | 771 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 450 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 70 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 61 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 655 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 875 | 0.040 |
Why?
|
| Exome | 1 | 2023 | 1249 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 2491 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 246 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 784 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 275 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 1249 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1080 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 2027 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 6432 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 2299 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 6776 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2014 | 63 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1699 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2014 | 91 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1732 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 2928 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 600 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 3213 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 4136 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 9041 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2391 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3441 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3343 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 4960 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14836 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 16646 | 0.010 |
Why?
|